-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-04-01
OPCH:NSD- (USD)
COMMON STOCK | Medical Care Facilities |
Last Closing
USD 34.95Change
0.00 (0.00)%Market Cap
USD 5.52BVolume
1.05MVerdict
Verdict
Values as of: 2025-04-01
COMMON STOCK | Medical Care Facilities |
Last Closing
USD 34.95Change
0.00 (0.00)%Market Cap
USD 5.52BVolume
1.05MVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
ENSG | The Ensign Group Inc |
N/A |
USD 7.42B |
SGRY | Surgery Partners Inc |
N/A |
USD 3.06B |
AMED | Amedisys Inc |
N/A |
USD 3.02B |
ACHC | Acadia Healthcare Company Inc |
N/A |
USD 2.79B |
LFST | Lifestance Health Group Inc |
N/A |
USD 2.67B |
ADUS | Addus HomeCare Corporation |
N/A |
USD 1.74B |
ASTH | Astrana Health Inc |
N/A |
USD 1.21B |
AVAH | Aveanna Healthcare Holdings In.. |
N/A |
USD 0.82B |
HCSG | Healthcare Services Group Inc |
N/A |
USD 0.76B |
CCRN | Cross Country Healthcare Inc |
N/A |
USD 0.55B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
WELL:PA | HAN-GINS Indxx Healthcare.. | 4.17 % | 0.00 % |
N/A |
N/A |
WELL:SW | HAN-GINS Indxx Healthcare.. | 4.17 % | 0.00 % |
N/A |
N/A |
MEDI | Harbor Health Care ETF | 4.05 % | 0.00 % |
N/A |
USD 0.02B |
VCAV:XETRA | 3.24 % | 0.00 % |
N/A |
N/A | |
CAVE:LSE | 3.09 % | 0.00 % |
N/A |
N/A | |
CVGB:LSE | 2.95 % | 0.00 % |
N/A |
N/A | |
CAVE:SW | 2.86 % | 0.00 % |
N/A |
N/A | |
QSML | WisdomTree U.S. SmallCap .. | 0.78 % | 0.00 % |
N/A |
USD 7.83M |
FESM | Fidelity Covington Trust | 0.78 % | 0.00 % |
N/A |
USD 2.22B |
GVLU | Tidal ETF Trust | 0.59 % | 0.00 % |
N/A |
USD 0.18B |
XHS | SPDR® S&P Health Care Se.. | 0.00 % | 0.35 % |
N/A |
USD 0.08B |
W311:XETRA | HAN-GINS Indxx Healthcare.. | 0.00 % | 0.00 % |
N/A |
N/A |
W311:F | HAN-GINS Indxx Healthcare.. | 0.00 % | 0.00 % |
N/A |
N/A |
Market Performance vs. Industry/Classification (Medical Care Facilities) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 50.65% | 88% | B+ | 96% | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 50.65% | 88% | B+ | 96% | N/A | ||
Trailing 12 Months | |||||||
Capital Gain | 9.25% | 85% | B | 73% | C | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 9.25% | 85% | B | 71% | C- | ||
Trailing 5 Years | |||||||
Capital Gain | 267.89% | 82% | B | 90% | A- | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 267.89% | 82% | B | 89% | A- | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 22.96% | 70% | C- | 78% | C+ | ||
Dividend Return | 22.96% | 70% | C- | 77% | C+ | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 33.61% | 59% | D- | 55% | F | ||
Risk Adjusted Return | 68.34% | 96% | N/A | 87% | B+ | ||
Market Capitalization | 5.52B | 96% | N/A | 89% | A- |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.